TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8404251

Group type: EXPERIMENTAL
Intervention: Intensive, in-home family-based services
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine out-of-home care services
Number of subjects: 110
Study: 3527111

Group type: EXPERIMENTAL
Intervention: Cyclosporine (n = 117)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Azathioprine-antilymphocyte globulin (n = 107)
Number of subjects: 224
Study: 4278962

Group type: EXPERIMENTAL
Intervention: 1% lidocaine solution
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: 4% lidocaine solution
Number of subjects: 199

Group type: COMPARATOR
Intervention: No topical lidocaine
Number of subjects: 199

Group type: COMPARATOR
Intervention: Topical lidocaine (1% or 4%) vs No topical lidocaine
Number of subjects: 199
Study: 30652920

Group type: EXPERIMENTAL
Intervention: Person-centred care plus standard cardiac care
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard cardiac care
Number of subjects: 199
Study: 28052214

Group type: EXPERIMENTAL
Intervention: Silver nanoparticle-mixed sealant
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional pit and fissure sealant
Number of subjects: 40
Study: 26011424

Group type: EXPERIMENTAL
Intervention: EPO (Eprex; 40,000 IU)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Saline (0.9% NaCl)
Number of subjects: 83
Study: 24263115

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1731
Study: 21673577

Group type: EXPERIMENTAL
Intervention: Telephone support (TS) group
Number of subjects: 3424

Group type: COMPARATOR
Intervention: Practice visit (PV) group
Number of subjects: 3424
Study: 19616778

Group type: EXPERIMENTAL
Intervention: 200 microg of oral misoprostol immediately after evacuation followed every 6 hours for 48 hours
Number of subjects: 160

Group type: COMPARATOR
Intervention: No misoprostol
Number of subjects: 160
Study: 16922750

Group type: EXPERIMENTAL
Intervention: Bevel oriented posteriorly
Number of subjects: 70
Study: 15763984

Group type: EXPERIMENTAL
Intervention: Integument reactions
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Hair loss
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Mucositis
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Rashes
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Palm and sole erythema
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Flexural erythema with desquamation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Drug allergies
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Patients' perception of skin problems
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Topical or systemic skin treatment
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Compromised oncology treatment
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Extra nursing required
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Longer hospital stay
Number of subjects: 84
Study: 11369677

Group type: EXPERIMENTAL
Intervention: Patients with right anterior temporal lobe removal
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Patients with left anterior temporal lobe removal
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 2
Study: 9431286

Group type: EXPERIMENTAL
Intervention: Stanford Nutrition Action Program
Number of subjects: 351

Group type: COMPARATOR
Intervention: General nutrition curriculum
Number of subjects: 351
Study: 8390044

Group type: EXPERIMENTAL
Intervention: BANA test incubated for 5 min at 35 degrees C
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BANA test incubated for 15 min at 35 degrees C
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BANA test incubated for 5 min at 45 degrees C
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BANA test incubated for 15 min at 45 degrees C
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BANA test incubated for 5 min at 55 degrees C
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BANA test incubated for 15 min at 55 degrees C
Number of subjects: 90
Study: 3030109

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 44

Group type: COMPARATOR
Intervention: Metronidazole-gentamicin
Number of subjects: 44
Study: 28304147

Group type: EXPERIMENTAL
Intervention: Higher dietary glycemic load (GL)
Number of subjects: 11159

Group type: EXPERIMENTAL
Intervention: Higher dietary glycemic index (GI)
Number of subjects: 11159

Group type: EXPERIMENTAL
Intervention: Higher intake of sugar and sugar-sweetened beverages
Number of subjects: 11159

Group type: EXPERIMENTAL
Intervention: Greater intake of dietary fiber
Number of subjects: 11159

Group type: EXPERIMENTAL
Intervention: Total carbohydrates or other carbohydrate-abundant foods
Number of subjects: 11159
Study: 28028947

Group type: EXPERIMENTAL
Intervention: Two-week cardiac rehabilitation program (interval training on a cycle ergometer)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Four-week cardiac rehabilitation program (interval training on a cycle ergometer)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Breathing exercises, active free exercises of the peripheral joints and different muscle groups, relaxation exercises (Control Group)
Number of subjects: 90
Study: 25552038

Group type: EXPERIMENTAL
Intervention: Ergoferon
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 23439910

Group type: EXPERIMENTAL
Intervention: Indoor tanning facilities allowing children as young as 10 or 12 years old to use indoor-tanning devices.
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Claiming that indoor tanning would prevent future sunburns.
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Claiming that there were no risks associated with indoor tanning.
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Intrasalon inconsistencies in allowable age of use and UVR exposure type and duration.
Number of subjects: 243
Study: 19969525

Group type: EXPERIMENTAL
Intervention: Transbond Plus
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Beauty Ortho Bond
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Transbond XT
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (24 hours storage)
Number of subjects: 126
Study: 18784631

Group type: EXPERIMENTAL
Intervention: Surgical intervention (spinal fusion techniques: postero-lateral fusion, interbody fusion, flexible stabilization)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Surgical intervention (complex procedures)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Surgical intervention (smoking and unemployment status)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Surgical intervention (litigation status)
Number of subjects: 106
Study: 16485575

Group type: EXPERIMENTAL
Intervention: FDG SPECT in low LVEF group
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: FDG SPECT in high LVEF group
Number of subjects: 47
Study: 15570414

Group type: EXPERIMENTAL
Intervention: Biochemical markers of bone turnover (serum osteocalcin, bone-specific alkaline phosphatase, deoxypyridinoline, pyridinolines, type I collagen cross-linked C-terminal telopeptide, serum intact parathyroid hormone, 1,25 dihydroxy vitamin D)
Number of subjects: 2535

Group type: EXPERIMENTAL
Intervention: Serum calcium, phosphorus, PTH and 1,25(OH)2D levels
Number of subjects: 2535

Group type: EXPERIMENTAL
Intervention: Diagnostic value of the markers
Number of subjects: 2535
Study: 10669269

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion with bupivacaine 1 mg/ml and fentanyl 10 mg/ml (F10)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion with bupivacaine 1 mg/ml and fentanyl 5 microg/ml (F5)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Saline (S) plus i.v. PCA
Number of subjects: 56
Study: 9086439

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin-B, median dose of 2.8 (0.64-5.09) mg/kg body-weight for 13 (1-55) days
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin-B
Number of subjects: 74
Study: 8444944

Group type: EXPERIMENTAL
Intervention: 6HR (isoniazid plus rifampicin for 6 months)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 9HR (isoniazid plus rifampicin for 9 months)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 9P/EH (isoniazid plus paraaminosalicylic acid or ethambutol for 9 months)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 18P/EH (isoniazid plus paraaminosalicylic acid or ethambutol for 18 months)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: All series (combined)
Number of subjects: 265
Study: 3896217

Group type: EXPERIMENTAL
Intervention: Terbutaline by wet nebulisation (5 mg, four times daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29684136

Group type: EXPERIMENTAL
Intervention: Group-mediated cognitive-behavioral exercise and dietary intervention (EX+D)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard-of-care (SC) control
Number of subjects: 32
Study: 27835953

Group type: EXPERIMENTAL
Intervention: Experience-based website containing personal accounts of quitting smoking
Number of subjects: 87

Group type: COMPARATOR
Intervention: Comparator website providing factual information
Number of subjects: 87
Study: 24576866

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (Ca-fortified beverage, 1 g·L)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 33
Study: 22182262

Group type: EXPERIMENTAL
Intervention: Seeking Safety (12 sessions)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Health education control condition
Number of subjects: 353
Study: 19493579

Group type: EXPERIMENTAL
Intervention: Persistent comorbid symptoms of depression and anxiety
Number of subjects: 2325

Group type: EXPERIMENTAL
Intervention: Combined presence of anxious and depressive symptoms
Number of subjects: 2325

Group type: EXPERIMENTAL
Intervention: Persistent depressive symptoms only
Number of subjects: 2325

Group type: EXPERIMENTAL
Intervention: Persistent anxious symptoms only
Number of subjects: 2325
Study: 18760153

Group type: EXPERIMENTAL
Intervention: Grip strength (affected dominant side)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Grip strength (affected nondominant side)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Action Research Arm Test (ARAT) (affected dominant side)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Action Research Arm Test (ARAT) (affected nondominant side)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) function score (affected dominant side)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) function score (affected nondominant side)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Motor Activity Log (MAL) quality of movement score (affected dominant side)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Motor Activity Log (MAL) quality of movement score (affected nondominant side)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Composite upper‐extremity strength (affected dominant side)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) time score (affected nondominant side)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Duration of upper‐extremity use (both affected sides)
Number of subjects: 52
Study: 16018819

Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Healon GV
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Healon 5
Number of subjects: 56
Study: 12821556

Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU and Vitamin C 1 g before supper
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU and Vitamin C 1 g before breakfast
Number of subjects: 11

Group type: COMPARATOR
Intervention: No vitamins, no test meal
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU and Vitamin C 1 g (timing not specified)
Number of subjects: 11
Study: 10591717

Group type: EXPERIMENTAL
Intervention: Hospital at home
Number of subjects: 199

Group type: COMPARATOR
Intervention: Hospital inpatient care
Number of subjects: 199
Study: 8929748

Group type: EXPERIMENTAL
Intervention: Metoprolol controlled release tablet (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bisoprolol normal release tablet (10 mg)
Number of subjects: 12
Study: 1899447

Group type: EXPERIMENTAL
Intervention: i.v. ribose (3.3 mg/kg/min x 30 min)
Number of subjects: 17

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 17
Study: 6405608

Group type: EXPERIMENTAL
Intervention: High nitrogen diet (364 mg/kg . day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low nitrogen diet (180 mg/kg . day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 10
Study: 31032879

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 514

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 514
Study: 29556759

Group type: EXPERIMENTAL
Intervention: Protective lipofilling
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no PMRT)
Number of subjects: 15
Study: 25648870

Group type: EXPERIMENTAL
Intervention: VIPS method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (conventional technique)
Number of subjects: 40
Study: 24766975

Group type: EXPERIMENTAL
Intervention: methylprednisolone
Number of subjects: 7500

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7500
Study: 22295066

Group type: EXPERIMENTAL
Intervention: Face mask and hand hygiene
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Face mask only
Number of subjects: 1178

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1178
Study: 20861631

Group type: EXPERIMENTAL
Intervention: Acid etching treatment (E)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No acid etching treatment (NE)
Number of subjects: 28
Study: 17996549

Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation directed at the C3 through C4 level
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham manual procedure (placebo)
Number of subjects: 72
Study: 15896425

Group type: EXPERIMENTAL
Intervention: Whole formula diet based on lyophilised foods (Treatment Group)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Nutritional advice (Control Group)
Number of subjects: 53
Study: 11952435

Group type: EXPERIMENTAL
Intervention: 2.5 microg/kg clonidine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 5.0 microg/kg clonidine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (no clonidine)
Number of subjects: 105
Study: 9892471

Group type: EXPERIMENTAL
Intervention: InteliSite capsule activated in the jejunum
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: InteliSite capsule activated in the ileum
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: InteliSite capsule activated in the colon
Number of subjects: 8
Study: 7649751

Group type: EXPERIMENTAL
Intervention: Composite model of hospital motivations for MRI adoption
Number of subjects: 507

Group type: COMPARATOR
Intervention: Individual models (profit maximization, technological preeminence, clinical excellence)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Composite model
Number of subjects: 507
Study: 2228036

Group type: EXPERIMENTAL
Intervention: NOR 400 mg t.i.d. for 10 days
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: NOR 800 mg b.i.d. for 10 days
Number of subjects: 37
Study: 84532

Group type: EXPERIMENTAL
Intervention: Protected environment-prophylactic antibiotic (PEPA) program
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no PEPA program)
Number of subjects: 58
Study: 31145185

Group type: EXPERIMENTAL
Intervention: Reengineered Discharge (RED) implementation in Standard SNFs
Number of subjects: 4

Group type: COMPARATOR
Intervention: Reengineered Discharge (RED) implementation in Enhanced SNFs
Number of subjects: 4
Study: 30666480

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) with Ketac Molar Easymix® (3 M ESPE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) with Vitro Molar® (DFL)
Number of subjects: 25
Study: 28253943

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with patellar resurfacing (TKAPR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Total knee arthroplasty without patellar resurfacing (TKA)
Number of subjects: 60
Study: 25338777

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 25607554

Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg daily for up to 24 weeks
Number of subjects: 596

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596
Study: 21537940

Group type: EXPERIMENTAL
Intervention: Dipyridamole monotherapy (200 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olanzapine (20 mg/day)
Number of subjects: 20
Study: 19827462

Group type: EXPERIMENTAL
Intervention: Immediate Feeding (IF): CHO-PRO solution (1.2 g CHO/kg BM and 0.4 g PRO/kg BM) immediately postexercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Delayed Feeding (DF): Water immediately postexercise, CHO-PRO solution 1 hr postexercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON): Water (12 ml/kg BM) immediately and 1 hr postexercise
Number of subjects: 9
Study: 18225472

Group type: EXPERIMENTAL
Intervention: Best practice 'case-management model' multifactorial intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 15159476

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM) supplementation (about 0.10 g/kg/day) for 4 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM) supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Corticosteroid use
Number of subjects: 30
Study: 12238654

Group type: EXPERIMENTAL
Intervention: HSV-1
Number of subjects: 4412

Group type: EXPERIMENTAL
Intervention: HSV-2
Number of subjects: 4412

Group type: EXPERIMENTAL
Intervention: Age distribution
Number of subjects: 4412

Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 4412

Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 4412

Group type: EXPERIMENTAL
Intervention: Geographical disparities
Number of subjects: 4412
Study: 9853540

Group type: EXPERIMENTAL
Intervention: Psyllium (1.3 g/day of soluble fiber)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Oat bran (2.6 g/day of soluble fiber)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (cookies with wheat bran)
Number of subjects: 66
Study: 8299777

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IV Ig) 500 mg/kg per month
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IV Ig)
Number of subjects: 27
Study: 2925707

Group type: EXPERIMENTAL
Intervention: Long thumb-spica cast
Number of subjects: 51

Group type: COMPARATOR
Intervention: Short thumb-spica cast
Number of subjects: 51
Study: 29967373

Group type: EXPERIMENTAL
Intervention: Biliary-type SOD patients undergoing ERCP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bile duct diameter ≥12 mm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Age ≥75 years
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 60
Study: 26996196

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 IU
Number of subjects: 56

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 56
Study: 23669452

Group type: EXPERIMENTAL
Intervention: Parent-led tactile stimulation (rubbing the ipsilateral thigh distal to the site for 15 seconds before, during, and after injections)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Parent-led tactile stimulation
Number of subjects: 120
Study: 23537313

Group type: EXPERIMENTAL
Intervention: Weekly (W) schedule with gemcitabine 1000 mg/m2 Day 1,8 + docetaxel 75 mg/m2 Day 1 q3W
Number of subjects: 241

Group type: COMPARATOR
Intervention: 3-weekly (3 W) schedule with gemcitabine 1000 mg/m2 Day 1,8 + docetaxel 75 mg/m2 Day 1 q3W
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Weekly (W) schedule with gemcitabine 1250 mg/m2 Day 1,8 + paclitaxel 175 mg/m2 Day 1 q3W
Number of subjects: 241

Group type: COMPARATOR
Intervention: 3-weekly (3 W) schedule with gemcitabine 1250 mg/m2 Day 1,8 + paclitaxel 175 mg/m2 Day 1 q3W
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Weekly (W) schedule with gemcitabine 800 mg/m2 Day 1,8,15 + docetaxel 30 mg/m2 Day 1,8,15 q4W
Number of subjects: 241

Group type: COMPARATOR
Intervention: 3-weekly (3 W) schedule with gemcitabine 800 mg/m2 Day 1,8,15 + docetaxel 30 mg/m2 Day 1,8,15 q4W
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Weekly (W) schedule with gemcitabine 800 mg/m2 Day 1,15 + paclitaxel 80 mg/m2 Day 1,8,15 q4W
Number of subjects: 241

Group type: COMPARATOR
Intervention: 3-weekly (3 W) schedule with gemcitabine 800 mg/m2 Day 1,15 + paclitaxel 80 mg/m2 Day 1,8,15 q4W
Number of subjects: 241
Study: 20518265

Group type: EXPERIMENTAL
Intervention: Barnett-Macků technique of anterior vaginal plastic surgery (BM; n=18)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Anterior plastic surgery with individualized mesh (Mesh; n=33)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Prolift with pre-set standard-size mesh (Prolift; n=36)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Post-operative assessment
Number of subjects: 87

Group type: COMPARATOR
Intervention: Post-operative assessment for urge
Number of subjects: 87
Study: 18533063

Group type: EXPERIMENTAL
Intervention: Tramadol plus remifentanil (TR)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tramadol (T)
Number of subjects: 62
Study: 16612557

Group type: EXPERIMENTAL
Intervention: Replanted fingers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal fingers (control)
Number of subjects: 20
Study: 14585013

Group type: EXPERIMENTAL
Intervention: Endogenous cuing with spread attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endogenous cuing with focused attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous cuing with spread attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous cuing with focused attention
Number of subjects: 0
Study: 11692899

Group type: EXPERIMENTAL
Intervention: Prednisolone (0.75 mg/kg for six months)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vitamin (control group)
Number of subjects: 19